Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PV-001-DV and PV-001-DC in Advanced Melanoma
NCT03989895Phase 1Unknown
- Sponsor
- PrimeVax Immuno-Oncology
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label, single-arm trial of PV-001-DV in melanoma, sponsored by PrimeVax Immuno-Oncology. Primary endpoint: Treatment-Emergent Adverse Events at 365 days. Status: unknown.
02
Drugs
PV-001-DV
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03989895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989895.